Trial Profile
Study on the influence of mCRP on the curative effect of herceptin on breast cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 21 May 2012 Planned End Date changed from 1 Dec 2013 to 1 Jan 2013 as reported by Chinese Clinical Trial Register.
- 08 Jan 2010 New trial record